Reperfusion is the most beneficial of all therapeutical strategies for acute ischemic stroke. Because of the risk of hemorrhage, especially in the brain, thrombolytic therapy is restricted by guidelines with the large amount of the inclusion and exclusion criterias adopted from the randomised clinical trials, and only a small number of the patients are begin treated.